CL2021002501A1 - Compuestos novedosos y métodos de uso de los mismos. - Google Patents

Compuestos novedosos y métodos de uso de los mismos.

Info

Publication number
CL2021002501A1
CL2021002501A1 CL2021002501A CL2021002501A CL2021002501A1 CL 2021002501 A1 CL2021002501 A1 CL 2021002501A1 CL 2021002501 A CL2021002501 A CL 2021002501A CL 2021002501 A CL2021002501 A CL 2021002501A CL 2021002501 A1 CL2021002501 A1 CL 2021002501A1
Authority
CL
Chile
Prior art keywords
methods
novel compounds
compounds
compositions
same
Prior art date
Application number
CL2021002501A
Other languages
English (en)
Inventor
Eamon Comer
Kenneth Duncan
Alexis Cocozaki
John Campbell
Darren Harvey
Michael MUNCHHOF
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CL2021002501A1 publication Critical patent/CL2021002501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos novedosos, composiciones que comprenden los compuestos y métodos de uso de los mismos.
CL2021002501A 2019-03-28 2021-09-27 Compuestos novedosos y métodos de uso de los mismos. CL2021002501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825507P 2019-03-28 2019-03-28
US201962952599P 2019-12-23 2019-12-23

Publications (1)

Publication Number Publication Date
CL2021002501A1 true CL2021002501A1 (es) 2022-06-17

Family

ID=70334131

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021002501A CL2021002501A1 (es) 2019-03-28 2021-09-27 Compuestos novedosos y métodos de uso de los mismos.
CL2022003206A CL2022003206A1 (es) 2019-03-28 2022-11-17 Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022003206A CL2022003206A1 (es) 2019-03-28 2022-11-17 Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)

Country Status (15)

Country Link
US (1) US20220144812A1 (es)
EP (1) EP3946623A1 (es)
JP (1) JP2022527279A (es)
KR (1) KR20210151849A (es)
CN (1) CN113891749A (es)
AU (1) AU2020244861A1 (es)
BR (1) BR112021019300A2 (es)
CA (1) CA3134826A1 (es)
CL (2) CL2021002501A1 (es)
CO (1) CO2021014351A2 (es)
IL (1) IL286649A (es)
MX (1) MX2021011699A (es)
PH (1) PH12021552389A1 (es)
SG (1) SG11202110591SA (es)
WO (1) WO2020198567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022138944A1 (es) * 2020-12-25 2022-06-30

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
CN101370782A (zh) * 2005-12-12 2009-02-18 阿斯利康(瑞典)有限公司 烷基磺酰胺喹啉
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101289460B (zh) * 2008-06-06 2011-09-14 山东大学 有机硼酸类化合物及其作为荧光探针的应用
US8466290B2 (en) * 2008-07-10 2013-06-18 Pharma Ip General Incorporated Association STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
MX382355B (es) * 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
AU2017302554A1 (en) 2016-07-25 2019-01-31 Epizyme, Inc. CREBBP related cancer therapy
WO2018058029A1 (en) * 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
HUE063405T2 (hu) * 2016-12-19 2024-01-28 Epizyme Inc Amin-szubsztituált heterociklusos vegyületek, mint EHMT2 inhibitorok és felhasználásuk módszerei

Also Published As

Publication number Publication date
JP2022527279A (ja) 2022-06-01
MX2021011699A (es) 2022-01-18
WO2020198567A8 (en) 2020-11-19
US20220144812A1 (en) 2022-05-12
CN113891749A (zh) 2022-01-04
SG11202110591SA (en) 2021-10-28
WO2020198567A1 (en) 2020-10-01
PH12021552389A1 (en) 2022-06-13
AU2020244861A1 (en) 2021-11-18
BR112021019300A2 (pt) 2021-12-14
KR20210151849A (ko) 2021-12-14
CA3134826A1 (en) 2020-10-01
CO2021014351A2 (es) 2022-01-17
CL2022003206A1 (es) 2023-07-07
EP3946623A1 (en) 2022-02-09
IL286649A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CL2021003373A1 (es) Nuevos inhibidores de egfr
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
CL2023000069A1 (es) Mezclas fungicidas
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
CR20190199A (es) Anticuerpos anti-pd-1 y sus usos
MX2019004690A (es) Constructos de anticuerpos.
MX2021006977A (es) Anellosomas y metodos de uso.
CL2019001249A1 (es) Composiciones de recubrimiento y métodos de uso de las mismas.
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
UY40794A (es) Formas cristalinas de (s)-afoxolaner
PY2027945A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
MX2021015879A (es) Peptidos restringidos.
PY2027936A (es) Hidroxiisoxazolinas y derivados de las mismas
PY2027939A (es) Hidroxiisoxazolinas y derivados de las mismas.-